Lithium, Elemental
Corticobasal Degeneration Disorder
WestatSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Corticobasal Degeneration Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Davunetide University of California, San Francisco | Phase 1 | CC |
Gosuranemab University of California, San Francisco | Phase 1 | CC |
Pittsburgh Compound B Unlabelled Mayo Clinic | Unknown | D |
Flortaucipir Mayo Clinic | Unknown | D |
ER-176 Mayo Clinic | Unknown | D |
Leucine Washington University School of Medicine | Unknown | D |
Same molecule, other indications
Lithium, Elemental is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →